CLAIMS

What is claimed is:

1. Use of a composition in the manufacture of a weaning formula for reducing the onset of allergies in a child of two years of age or older, wherein the composition comprises

(a) from 3 g/100 kcal to 7 g/100 kcal of a fat or lipid source,

(b) from 8 g/100 kcal to 12 g/100 kcal of a carbohydrate source, wherein the carbohydrate source comprises between 15% and 55% lactose by weight,

(c) a probiotic source comprising *Lactobacillus rhamnosus* GG,

(d) a non-human lactoferrin,

(e) a prebiotic source comprising galactooligosaccharide and polydextrose, wherein the prebiotic source is present in an amount of from 0.1 g/100 kcal to 1 g/100 kcal; and

(f) a protein source comprising whey and casein proteins, wherein the protein source is present in an amount of from 1 g/100 kcal to 5 g/100 kcal, wherein the ratio of whey to casein proteins in the protein source is from 50:50 to 70:30 by weight and wherein the degree of hydrolysis of the whey and casein proteins included in the protein source is from 4% to 10%,

wherein when the child is an infant, the weaning formula is to be administered to the child and administration of the weaning formula increases the concentration of fecal secretory IgA in the child.

2. The use of claim 1, wherein the child has a family history of allergies.

3. The use according to claim 1, wherein the child is at risk of developing one or more allergic manifestations selected from the group consisting of allergic colititis, allergic enterocolitis, allergic esophagatis, allergic gastroesophagitis, allergic urticaria, atopic dermatitis, an allergic reaction to cow's milk, an allergic reaction to egg, an allergic reaction to soy, an allergic reaction to house dust, an allergic reaction to mites, gut inflammation and combinations thereof.

4. The use according to claim 1, wherein the carbohydrate source comprises between 20% and 30% lactose by weight.

5. The use according to claim 1, wherein the degree of hydrolysis of the whey and casein proteins included in the protein source is from 6% to 9%.

6. The use according to claim 1, wherein the whey and casein proteins in the protein source have the following molecular weight distribution:

Molar Mass (in Daltons)	% Molecular Weight Distribution
<500	11-20
500-1000	25-38
1000-2000	27-30
2000-3000	8-16
3000-5000	3-10
>5000	2-11.

7. The use according to claim 1, wherein the whey and casein proteins in the protein source have the following molecular weight distribution:

Molar Mass (in Daltons)	% Molecular Weight Distribution
<500	17
500-1000	35.1
1000-2000	30.9
2000-3000	9.6
3000-5000	4.2

>5000	2.8.

8. Use of a composition in the manufacture of a weaning formula for reducing the onset of allergies in a human, wherein the composition comprises

(a) from 3 g/100 kcal to 7 g/100 kcal of a fat or lipid source,

(b) from 8 g/100 kcal to 12 g/100 kcal of a carbohydrate source, wherein the carbohydrate source comprises between 15% and 55% lactose by weight,

(c) a probiotic source comprising *Lactobacillus rhamnosus* GG,

(d) a non-human lactoferrin,

(e) a prebiotic source comprising galactooligosaccharide and polydextrose, wherein the prebiotic source is present in an amount of from 0.1 g/100 kcal to 1 g/100 kcal; and

(f) a protein source comprising whey and casein proteins, wherein the protein source is present in an amount of from 1 g/100 kcal to 5 g/100 kcal, wherein the ratio of whey to casein proteins in the protein source is from 50:50 to 70:30 by weight and wherein the degree of hydrolysis of the whey and casein proteins included in the protein source is from 4% to 10%,

wherein when the human is an infant, the weaning formula is to be administered to the human and administration of the weaning formula increases the concentration of fecal secretory IgA in the human.

9. The use according to claim 8, wherein the human has a family history of allergies.